Michael Rossi: Advancing Clinical Cancer Research With NGS

May 2, 2016

Michael Rossi, Phd discusses the important role of next-generation sequencing (NGS) in clinical cancer research. www.illumina.com/cancer Dr. Rossi explains how NGS enables researchers to cost-effectively assess multiple genes in a single test. He emphasizes partnership with pathologists and concludes by encouraging newcomers to make the move to NGS to accelerate progress in clinical cancer research. Presenter: Michael Rossi PhD, Assistant Professor, Department of Radiation Oncology, Emory University School of Medicine Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc View other cancer genomics videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaiQbVkCco7Kre3KkyElP04h View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.